Wells Fargo’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-18,900
| Closed | -$4.89M | – | 7507 |
|
|
2023
Q4 | $4.89M | Hold |
18,900
| – | – | ﹤0.01% | 2224 |
|
|
2023
Q3 | $4.86M | Buy |
+18,900
| New | +$5.06M | ﹤0.01% | 2133 |
|
|
2023
Q2 | – | Sell |
-4,100
| Closed | -$1.14M | – | 7586 |
|
|
2023
Q1 | $1.14M | Buy |
+4,100
| New | +$1.13M | ﹤0.01% | 3285 |
|
|
2021
Q4 | – | Sell |
-7,500
| Closed | -$2.12M | – | 7221 |
|
|
2021
Q3 | $2.12M | Sell |
7,500
-8,000
| -52% | -$2.62M | ﹤0.01% | 3623 |
|
|
2021
Q2 | $5.37M | Buy |
15,500
+7,500
| +94% | +$2.27M | ﹤0.01% | 2806 |
|
|
2021
Q1 | $2.24M | Buy |
+8,000
| New | +$2.16M | ﹤0.01% | 3589 |
|
|
2019
Q4 | – | Sell |
-100
| Closed | -$8K | – | 6353 |
|
|
2019
Q3 | $8K | Hold |
100
| – | – | ﹤0.01% | 5974 |
|
|
2019
Q2 | $8K | Hold |
100
| – | – | ﹤0.01% | 5950 |
|
|
2019
Q1 | $8K | Sell |
100
-908
| -90% | -$286K | ﹤0.01% | 5664 |
|
|
2018
Q4 | $36K | Sell |
1,008
-8
| -0.8% | -$2.55K | ﹤0.01% | 5623 |
|
|
2018
Q3 | $14K | Buy |
1,016
+407
| +67% | +$140K | ﹤0.01% | 5906 |
|
|
2018
Q2 | $7K | Buy |
609
+9
| +2% | +$2.53K | ﹤0.01% | 6023 |
|
|
2018
Q1 | $17K | Buy |
+600
| New | +$186K | ﹤0.01% | 5835 |
|
|
2017
Q4 | – | Sell |
-900
| Closed | -$4K | – | 6343 |
|
|
2017
Q3 | $4K | Buy |
+900
| New | +$267K | ﹤0.01% | 6056 |
|
|
2017
Q1 | – | Sell |
-25,300
| Closed | -$429K | – | 6302 |
|
|
2016
Q4 | $429K | Sell |
25,300
-17,500
| -41% | -$5.19M | ﹤0.01% | 4306 |
|
|
2016
Q3 | $575K | Buy |
+42,800
| New | +$12.7M | ﹤0.01% | 3868 |
|
|
2016
Q2 | – | Sell |
-10,000
| Closed | -$364K | – | 6099 |
|
|
2016
Q1 | $364K | Sell |
10,000
-14,200
| -59% | -$3.75M | ﹤0.01% | 4060 |
|
|
2015
Q4 | $356K | Buy |
24,200
+10,000
| +70% | +$2.87M | ﹤0.01% | 4110 |
|
|
2015
Q3 | $462K | Sell |
14,200
-2,500
| -15% | -$826K | ﹤0.01% | 3990 |
|
|
2015
Q2 | $143K | Buy |
16,700
+4,900
| +42% | +$1.97M | ﹤0.01% | 4803 |
|
|
2015
Q1 | $48K | Buy |
11,800
+100
| +0.9% | +$39.4K | ﹤0.01% | 5025 |
|
|
2014
Q4 | $302K | Buy |
+11,700
| New | +$3.79M | ﹤0.01% | 4218 |
|
Other funds holding BIIB
Wells Fargo's BIIB Position: Q2 2026 in Review
Wells Fargo increased its Biogen (BIIB) stake by 1.2% in Q2 2026, buying an estimated $293K and bringing the position to 128,664 shares worth $27.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1396.
Wells Fargo first reported a position in BIIB in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.02B in Q1 2015. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Wells Fargo held 128,664 shares of Biogen worth $27.8M as of Q2 2026.
- Wells Fargo bought 1,530 Biogen shares in Q2 2026, an estimated $293K.
- Biogen made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #1396 holding.
- Wells Fargo first reported a position in Biogen in Q2 2013 and has held it in 53 quarters since.
- Wells Fargo's Biogen position peaked at $1.02B in Q1 2015.
- 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.